What’s inside
View ResearchExplore the discovery of genes modulating MHC-I and MHC-II immunosurveillance in human lymphomas through genome-wide CRISPR screening. This study identifies numerous regulators of antigen presentation, revealing tumor-specific mechanisms affecting immune evasion and suggesting potential therapeutic targets. The findings highlight the role of SUGT1 and pharmacological inhibitors of EZH2 and thymidylate synthase in enhancing tumor immunogenicity, promising advancements in cancer immunotherapy.
MHC-I and MHC-II Regulation in Lymphomas
Discover lineage- and tumor-specific genes modulating MHC-I and MHC-II immunosurveillance in human lymphomas.
Genome-Wide CRISPR Screening in DLBCL
Using genome-wide CRISPR screens to identify novel MHC-I regulators in diffuse large B cell lymphoma.
SUGT1's Role in Antigen Presentation
Study reveals SUGT1 as a key positive regulator of both MHC-I and MHC-II surface expression in lymphomas.
Enhancing Immunotherapy in DLBCL
Targeting EZH2 and thymidylate synthase to enhance antigen presentation and immunotherapy in DLBCL.
Genetic Alterations in MHC-I Pathway
Analysis of genetic mutations and alterations in MHC-I regulators across 574 DLBCL patient samples.
Pharmacological Targets for DLBCL
Exploring the potential of EZH2 and thymidylate synthase inhibitors to improve immunotherapy in DLBCL.
.svg)
.jpg)
.webp)
